The research team, led by Chengchi Xia, Tianshu Rong, and Baoqing Wang of the Second Affiliated Hospital of Xuzhou Medical University, extracted mortality records from the United States Multiple Cause of Death database for adults aged 25 and older between 1999 and 2023. They identified cases in which the underlying cause of death involved both a malignant neoplasm, coded C00 through C97 in the International Classification of Diseases, Tenth Revision, and respiratory failure, captured by codes J96.0 for acute failure, J96.1 for chronic failure, and J96.9 for unspecified failure. This dual-coding approach means the analysis captures deaths in which cancer was the fundamental cause but respiratory failure was the immediate clinical event that precipitated the end of life.

The raw numbers are striking. Respiratory failure-associated deaths among adult cancer patients rose from 36,812 in 1999 to 79,968 in 2023, an increase of 117.23 percent. The age-adjusted mortality rate, standardized to the 2000 US population to account for demographic shifts, climbed from 20.78 per 100,000 in 1999 to 28.42 per 100,000 in 2023. Yet when the researchers fitted log-linear regression models across the entire period using Joinpoint regression software, the average annual percent change came out at negative 0.60 percent, a statistically significant long-term decline. The apparent contradiction between rising absolute deaths and a net downward rate reflects both population growth and the aging of the American population, which pushed more people into the highest-risk age brackets even as age-standardized rates improved for most of the period.

That improvement, however, was not smooth. Joinpoint analysis, which is designed to detect inflection points in mortality time series, revealed a synchronized reversal across all subgroups between 2018 and 2021. Among men, the annual percent change during that window was 5.02 percent, with a 95 percent confidence interval of 3.52 to 6.55. Among women it was 5.56 percent, with a confidence interval of 3.29 to 7.89. Before that inflection, male mortality had fallen at 2.15 percent annually from 1999 to 2014 and female mortality at 1.74 percent annually from 1999 to 2015. After 2021, both trends returned to statistical stability. The authors attribute this collective surge to a convergence of two forces: the COVID-19 pandemic, which hit immunosuppressed cancer patients with particular severity, and the cumulative pulmonary toxicity of modern oncological therapies.

The pathophysiology underlying this pattern is layered. Respiratory failure in cancer patients can arise through direct neoplastic mechanisms, such as tumor invasion of lung parenchyma, metastatic infiltration, or compressive airway obstruction, and through indirect systemic pathways including paraneoplastic syndromes, cancer-associated cachexia, and generalized frailty. Superimposed on these is treatment-related lung injury, which can be triggered by localized radiotherapy, cytotoxic chemotherapy, and newer targeted agents. Immune checkpoint inhibitors, which have transformed survival in melanoma, lung cancer, and many other malignancies, are also associated with immune-mediated pneumonitis that can progress to acute respiratory distress syndrome or interstitial pneumonia. As precision medicine extends survival, patients live longer with lungs that have accumulated damage from multiple pneumotoxic regimens, a phenomenon the authors describe as a survival paradox.

The pandemic amplified these vulnerabilities in ways the data make visible. Cancer patients, by virtue of immunosuppression from both their disease and its treatment, faced a lowered physiological threshold for SARS-CoV-2 infection to progress into acute respiratory failure. At the same time, the reallocation of intensive care resources and the deferral of routine oncological screening during 2020 and 2021 may have allowed cancers to be diagnosed at more advanced stages, increasing terminal complications. The surge in mortality between 2018 and 2021 was disproportionately concentrated in non-metropolitan areas and among minoritized populations, suggesting that the acute shock of COVID-19 did not create health disparities so much as it exposed and intensified long-standing structural ones.

Those disparities are among the study’s most consequential findings. In 2023, non-Hispanic Black individuals had an age-adjusted mortality rate of 34.56 per 100,000, well above the 29.13 rate for non-Hispanic White individuals, the 22.07 rate for Hispanic populations, and the 19.48 rate for the non-Hispanic Other category. The authors point to a higher prevalence of shared cardiopulmonary risk factors, including smoking, obesity, and chronic obstructive pulmonary disease, as one mechanism, and cite evidence suggesting heightened susceptibility to arterial stiffness and elevated peripheral resistance among Black Americans, which may reduce tolerance for treatment-related complications. Socioeconomic inequities and differential access to healthcare resources compound these biological and behavioral factors.

Geography tells a parallel story. State-level analysis revealed an extreme range in mortality, from 15.6 per 100,000 in Maine to 58.4 per 100,000 in Mississippi, meaning residents of the highest-burden states face a risk nearly 3.7 times greater than those in the lowest. The urban-rural divide proved especially durable: metropolitan areas saw a significant long-term decline in mortality, with an average annual percent change of negative 1.15 percent, while non-metropolitan areas remained essentially flat at negative 0.18 percent, a difference the authors describe as an entrenched divergence. By 2023, the non-metropolitan rate of 30.52 per 100,000 exceeded the metropolitan rate of 25.25. The researchers attribute this gap to a cascading failure in rural healthcare access, where chronic shortages of primary care physicians delay cancer screening and diagnosis, and where resource-constrained hospitals cannot provide the lung-protective ventilation strategies and non-invasive respiratory support available in urban tertiary centers.

Looking forward, the team constructed autoregressive integrated moving average models to project mortality trajectories through 2046. Under the assumption that prevailing trends continue, the overall age-adjusted rate is forecast to rise from 28.4 per 100,000 in 2023 to 42.4 in 2046, an increase of roughly 49.2 percent. Men are projected to reach 44.9 per 100,000, while women, despite starting from a lower baseline of 24.3, are projected to experience the largest percentage increase, reaching 38.8 per 100,000, a jump of 59.7 percent. The authors are careful to frame these projections as heuristic scenarios rather than definitive forecasts. The 95 percent confidence intervals are exceptionally wide, spanning from 14.9 to 75.0 per 100,000 for the male cohort, reflecting the inherent volatility of extrapolating from a period that includes a global pandemic.

The study has limitations the authors acknowledge candidly. Reliance on ICD-10 codes introduces diagnostic non-specificity, since respiratory failure is sometimes recorded as a terminal coding diagnosis that reflects the physiological dying process rather than a specific oncological complication. The absence of granular clinical data on cancer staging, respiratory failure severity, and specific treatment regimens prevents definitive causal attribution to any single pneumotoxic therapy. Unmeasured confounders such as individual socioeconomic status and screening intensity may also shape the observed patterns. Still, the central message is difficult to dismiss: as cancer care extends lives, the lungs of survivors are emerging as a critical battleground, and the researchers argue that institutionalizing collaboration between oncology and pulmonary medicine, along with targeted screening for high-risk populations, is essential to prevent the projected escalation from becoming reality.

Subject of Research: Mortality trends from respiratory failure among US adult cancer patients from 1999 to 2023

Article Title: Trends in cancer-and respiratory failure-related mortality in the US adult population: an analysis of the CDC WONDER database from 1999 to 2023

Article References: Xia, C., Rong, T., & Wang, B. (2026). Trends in cancer-and respiratory failure-related mortality in the US adult population: an analysis of the CDC WONDER database from 1999 to 2023. Frontiers in Cancer Control and Society, 4, Article 1752674. https://doi.org/10.3389/fcacs.2026.1752674

Image Credits: AI Generated

DOI: 10.3389/fcacs.2026.1752674

Keywords: respiratory failure, cancer mortality, CDC WONDER, health disparities, COVID-19, pulmonary toxicity, age-adjusted mortality rate, rural health, immune checkpoint inhibitors, joinpoint regression, ARIMA forecasting, cancer survivorship